Free Trial

Relay Therapeutics Q4 2024 Earnings Report

Relay Therapeutics logo
$3.66 +0.25 (+7.33%)
As of 03/14/2025 04:00 PM Eastern

Relay Therapeutics EPS Results

Actual EPS
-$0.45
Consensus EPS
-$0.57
Beat/Miss
Beat by +$0.12
One Year Ago EPS
N/A

Relay Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
$5.53 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Relay Therapeutics Announcement Details

Quarter
Q4 2024
Time
After Market Closes

Conference Call Resources

Remove Ads

Relay Therapeutics Earnings Headlines

A market crash is coming—here’s when
The stock market cycle I've used to identify the most likely day of the next market crash is the exact same indicator that helped me call the bear market of 2018... the bull market in 2020... the bear market in 2022... the roaring bull markets in 2023 and 2024... and more. I'm convinced it has helped me identify the next big crash too. We are at an important juncture in the markets. Knowing what to do in the months to come is critical.
Relay Therapeutics price target lowered to $12 from $21 at Citizens JMP
Relay Therapeutics reports Q4 EPS (45c), consensus (55c)
See More Relay Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Relay Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Relay Therapeutics and other key companies, straight to your email.

About Relay Therapeutics

Relay Therapeutics (NASDAQ:RLAY) operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

View Relay Therapeutics Profile

More Earnings Resources from MarketBeat